Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.

Leukemia research - 1 Aug 2026

Kapoor Nilesh, Hoff Fieke W, Jackson Clayton, Gatell Vivian Irizarry, Arslan Shukaib, Velarde Alejandro Marinos, Collins Robert H, Chung Stephen S, Madanat Yazan F

Abstract excerpt

BACKGROUND: Isocitrate dehydrogenase inhibitors (IDHi) for IDH-mutated acute myeloid leukemia (AML) are important treatment options for older adults in whom treatment-related toxicities are a major concern. Long-term data on IDHi are limited. METHODS: We conducted a single-center retrospective study of patients aged ≥ 65 years with newly diagnosed or relapsed/refractory IDH-mutated AML who received ivosidenib or...

Topics

Join the communities discussing this publication.

Aminopyridines
Enzyme Inhibitors
Glycine
Isocitrate Dehydrogenase
Pyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Remission Induction

Source

Identifiers

PMID: 42335650
DOI: 10.1016/j.leukres.2026.108268

Genes

EFS
IDH1
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.PMID 42335650Read ↗

Long-term (74-month) efficacy and safety of ivosidenib and azacitidine in an elderly patient with mutated IDH1 acute myeloid leukemia: insights from a case report.Semantic proximity Read ↗

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.Semantic proximity Read ↗

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis.Semantic proximity Read ↗

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.Semantic proximity Read ↗

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.Semantic proximity Read ↗

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.Semantic proximity Read ↗

Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.Semantic proximity Read ↗

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.Semantic proximity Read ↗

IDH Inhibitors in AML-Promise and Pitfalls.Semantic proximity Read ↗

Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.Semantic proximity Read ↗

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.